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ABSTRACT 
Introduction 
The objective is to assess tracheal reactivity after the deployment of different self-expandable 
metallic stents (SEMS). 
Material and methods 
40 New Zealand female rabbits were divided into four groups. Three groups tested SEMS: 
steel (ST), nitinol (NiTi), and nitinol drug eluting stent (DES).The fourth group was the 
control group (no stent). 
Stents were deployed percutaneously under fluoroscopic control. Animals were assessed by 
multi-slice, computed tomography (CT) scans, and tracheas were collected for 
anatomopathological (AP) study. Data from CT and AP were statistically analyzed and 
correlated. 
Results 
DES group had the longest stenosis (20.51±14.08 mm vs 5.84±12.43 and 6.57±6.54 mm in 
NiTi and ST, day 30; p<0.05), and the higher granuloma formation at CT study (50% of 
  
 
cases). NiTi group showed the lowest degree of stenosis (2.86±6.91% vs 11.28±13.98 and 
15.54±25.95% in DES and ST; p<0.05). 
In AP, ST group developed a intense proliferative reactivity compared to the other groups. In 
DES, there was a destructive response in 70% of the animals, while NiTi was the less reactive 
stent. 
CT was superior in detecting wall thickening (positive correlation of 68.9%;p<0.001) than 
granuloma (NS). 
Conclusions 
The ST group developed granulomas and significant stenosis. NiTi was the least reactive, and 
DES caused significant lesions that may be related to drug dosage. Therefore, this type of 
DES stents is not recommended for the treatment of tracheobronchial stenosis.  
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MAIN TEXT 
INTRODUCTION  
Even though surgical exeresis is the primary procedure for the treatment of tracheobronchial 
stenosis 1, tracheal stenting provides satisfactory management of central airway obstruction in 
non-surgical patients, along with other minimally invasive techniques, such as 
radiofrequency, laser ablation, and cryotherapy 2. Silicone prostheses are the most commonly 
used, but these require the use of a rigid bronchoscope with general anesthesia for 
implantation. In contrast, metallic stents can be deployed by fluoroscopy or through a flexible 
  
 
fibrobroncoscope or endotracheal tube under light sedation, providing immediate 
symptomatic relief 3. Other advantages of metallic over silicone stents are their higher radial 
force, better internal to external diameter ratio, less incidence of migration, and decreased risk 
of mucus obstruction and bacterial colonization 4  However, these important advantages have 
been clouded by their long-term complications (such as restenosis due to granuloma 
formation or tumor growth), and the difficulty of their removal 5. These issues caused the 
Food and Drug Administration (FDA) in 2005 to advise against the use of metallic stents in 
benign lesions 6. 
Nevertheless, since 2005, studies have reported that metallic stents are safe for the treatment 
of benign and malignant tracheobronchial stenosis 6-9. Restenosis, due to intraluminal 
overgrowth, has mainly been described for steel stents 10. Studies with laser cut, self-
expandable nitinol stents have had better results. However, these nitinol stents are mostly 
used for other territories such as cardiovascular and biliary tree indications. Antiproliferative 
drugs are used in cardiovascular indications to avoid restenosis 11,12, but experience on the 
airway is limited.  
We hypothesized that DES may merge the advantages of the metallic stents in tracheal 
stenosis management, while avoiding or attenuating restenosis from intraluminal overgrowth 
through the mesh and over the ends. Therefore, the purpose of this study was to assess the 
tracheal responses to three different SEMS (drug-eluting nitinol, nitinol and stainless steel 
bare stents) in an animal model. 
METHODS  
Animals and stents 
  
 
Forty New Zealand, adult female rabbits (3.95 ± 0.48 kg) were used in this study. The care 
and use of animals complied with the European Communities Council Directive 
(86/609/EEC) and the local animal welfare laws, guidelines and policies, and was approved 
by the ethical committee of the Universidad de Zaragoza. They were randomly distributed 
into four groups: ST (n=10), steel stent (Wallstent™, Boston Scientific, Natick, MA. USA); 
NiTi (n=10), nitinol stent (Zilver®Flex™ Vascular Stent,Cook Medical, Bjaeverskov, 
Denmark); DES (n=10), paclitaxel-eluting nitinol stent (Zilver®PTX® Drug Eluting 
Peripheral Stent, Cook Medical, Bjaeverskov, Denmark) and control (n=10), with no stent. 
Both nitinol stents are laser-cut and share exactly the same pattern design, whereas the steel 
stent is braided wire. All stents were self-expandable and measured 8x40 mm, at a 1:1 ratio to 
the trachea of the animal model. The stents were deployed percutaneously under general 
anesthesia and fluoroscopic guidance. Animals were followed for 90 days. 
Stenting technique 
Before stent implantation, all rabbits were checked for sanitary status and fasted for 8 h. They 
were medicated intramuscularly with 0.5 mg/kg medetomidine (Sedator®, Eurovet Animal 
Health, The Netherlands) and 25 mg/kg ketamine (Imalgene 1000®, Merial, Barcelona, 
Spain). Anaesthesia was maintained with 1–2% isofluorane (Isovet, Braun, Barcelona, Spain) 
by inhalation. Animals were monitored throughout the procedure (Samurai anaesthetic 
equipment, La Bouvet, Madrid, Spain and Dash 3000 monitor, General Electric Company, 
Helsinki, Finland). 
After positioning animals in supine recumbency and neck hyperextension, and administering 
50 mg/kg of oxitetracicline (Terramicina LA, Pfizer, Madrid, Spain), a 5F centimeter-sizing, 
straight catheter (Aurous®. Cook Medical. Bjaeverskov, Denmark) was introduced into the 
esophagus to get a measure reference. Tracheal access was gained by puncturing between the 
  
 
two most cranial tracheal rings using an 18 G catheter-over-needle (Introcan®, Braun, 
Germany), then 0.15 ml lidocaine (Braun, Barcelona, Spain), was introduced into the trachea. 
A 0.035 inch hydrophilic guide wire (Radifocus® Guide Wire M Standard type, Terumo, 
Leuven, Belgium), soaked in lidocaine, was advanced into the trachea, and the catheter was 
removed. The stent delivery system was inserted directly over the guide wire and placed at a 
defined position (distal mark of the stent, 1 cm cranial to the tracheal carina) where the stent 
was deployed under fluoroscopic control (C-arm system BV Endura, Philips, Eindhoven,The 
Netherlands). Once placed, the delivery system, the guide wire, and the centimeter catheter 
were removed, and the animal was supervised until recovery (Fig.1). 
All procedures were performed equally for the control group, using a delivery stent system 
without a stent.   
Follow-up and CT study 
After stent placement, all animals were observed for any sign of respiratory tract obstruction 
and surgical wound infection. The general health status of the animals was assessed by daily 
clinical examinations. 
In cases of death before the end of the study, samples were obtained and processed 
immediately as per protocol. The only test that was not possible to do in case of death was CT 
scanning. 
CT tracheal studies were performed under sedation 30 and 90 days after stent deployment 
(Phillips Brilliance CT 16-slice, The Netherlands). CT scans were performed with 1 mm slice 
thickness, 0.5 mm inter-slice gap, pitch 0.69, and three dimensional reconstructions were 
obtained. 
  
 
Parameters assessed in the CT study were: maximum tracheal lumen stenosis in an axial view 
(%), stenosis length in a sagittal view (mm), and detection of image compatible with 
granulomas (present or absent).  
A stenosis score was also calculated, as described in Table 1, to better evaluate the entire 
trachea. Five sections in each trachea were defined to simplify CT interpretation: P, tissue 
immediately cranial to the proximal end of the stent; 0, proximal end of the stent; 2, central 
part of the stent; 4, distal end of the stent; and D, tissue immediately caudal to the distal end 
of the stent. 
CT studies were blindly reviewed by two senior radiologists who scored each case 
independently. In cases of disagreement, a third observer was consulted. 
AP study 
Animals were sacrificed at day 90 by intravenous sodium pentobarbital injection (Dolethal®, 
Vétoquinol, France), and the trachea was sampled for AP studies. 
The complete trachea was fixed in 10% formaldehyde. The part containing the metallic stent 
was embedded in methyl methacrylate, cut by a diamond band saw microtome (EXAKT 310 
CS/CP, Norderstedt, Germany), and polished into 8µm-thick sections (EXAKT 400CS 
Norderstedt, Germany). The segments immediately cranial and caudal to the stents and the 
total trachea of the control group were paraffin-embedded, and cut into 3-5 µm-thick sections 
(Leica Reichert-Jung BIOCUT 2030 Microtome, Wetzlar, Germany). Samples were stained 
with hematoxylin-eosin and studied in an optical microscope (Nikon Eclipse 80i, Nikon 
Instruments Europe).  
The same five sections (P, 0, 2, 4, D) defined for the CT study were also used for the 
histological study. Parameters studied in histology were: epithelial and subepithelial 
  
 
thickness, modification in respiratory epithelium, squamous metaplasia, granuloma formation, 
and inflammation and vascularization. Some of them were scored according to Table 1. 
Statistical analysis 
All data processing and statistical analyses were performed using SPSS Statistics 17.0 for 
Windows. An α error of 0.05 was established. Qualitative variables were expressed as 
frequencies, while quantitative variables were described as mean ± standard deviation. 
Qualitative variables were compared using the Likelihood Ratio test. 
Before comparison, normality of quantitative variables was tested using the Kolmorov-
Smirnov test. If the data were normally distributed, the Student’s t-test for independent 
samples (two means) or analysis of variance, ANOVA (more than two means), were applied. 
For non-normal distributions, the Mann-Whitney U test or Kruskal-Wallis tests were applied. 
In cases of ordinal variables, the Wilcoxon test was used. 
Correlations were assessed using Spearman´s correlation coefficient (ρ) and the 
corresponding coefficients of determination (ρ2). 
RESULTS  
The technical success of implantation was 100%. There were no immediate deaths or major 
complications due to this procedure. 
Although most animals were sacrificed at day 90, eight animals (80%) of the ST group died 
(mean: 31.4 days post-intervention); 2 animals (20%) died in the NiTi group (mean: 39.5 
days); 4 animals (40%) of the DES group died (mean: 14.5 days). All deaths were due to 
causes related to the stent, such as stenosis and infection. 
CT Study 
  
 
Stenosis degree.- The maximum tracheal stenosis (%) and its location at days 30 and 90 are 
represented in Table 2. Whereas maximum tracheal stenosis was located at the proximal end 
in the steel group, the central segment was more affected in the nitinol group (Fig. 2). 
Stenosis scores in each group are summarized in Table 3. The ST and DES groups developed 
higher, but not statistically significant, scores at both days. 
Stenosis length.- At day 30 post-implantation, the DES group presented significantly longer 
stenosis than the other two groups. In all groups, the stenosis length increased at day 90, but 
stenosis length in the ST and NiTi groups increased more than in the DES group (Table 2). 
There were no statistical differences between the groups at day 90, or between days 30 and 90 
within the same group. 
Granuloma Formation.- All groups appeared to have granulomas, which were located in 
segments 0 and/or 2 (Fig. 3). Scans from the DES group had the greatest intensities of these 
suspected granulomas. The percentage of cases in the DES group with an apparent granuloma 
was statistically significant in segment 2 at day 30 (50%, p=0.010), and in segment 0 at day 
90 (50%, p=0.018). There were no statistically significant differences in the other groups. 
AP study  
All AP scores are summarized in Table 4 and AP images are presented in Figure 4. 
ST group.- The gross AP result of the ST group was characterized by a thickening of the 
tracheal wall and significant formation of new vessels. There was an increase of goblet cells 
and decrease of ciliated ones. The percentage of cases of squamous metaplasia was 
statistically higher in this group throughout the trachea (p<0.001). Granuloma formation, 
mainly observed at the ends of the stent, was also statistically higher in this group. (44.4% of 
cases). In fact, this was the only group in which more than one granuloma was observed in the 
same section (11.1% of cases). Acute and chronic inflammation was also observed in this 
  
 
group, but only acute inflammation was statistically higher than the other groups (p<0.001). 
New vessel formation was also statistically higher in the ST group (between 22.2% and 
55.6% of cases; p<0.001), comparing to the other groups. 
NiTi group.- The nitinol stent caused fewer cases of epithelial and subepithelial thickening, 
which was mild to moderate in appearance, but not severe. The proportion of goblet and 
ciliated cells was mostly maintained, and in cases of alteration, the disproportion was mild 
and primarily located at the ends of the stent. We observed squamous metaplasia in segment 4 
of 25% of cases, although it was not statistically significant. Few granulomas were detected 
(12.5% and 10%, at segments 4 and D, respectively) in this group, and had less inflammation 
and neovascularization. 
DES group.- DES caused the destruction of the tracheal structure in 7 animals (70%), and 
stent struts were observed throughout the tracheal wall, with adherences to the surrounding 
tissue. The epithelium was destroyed in a significant number of cases (40% at the proximal 
part, 60% at the distal part and 30% at the parts in contact with the stent). Although the 
epithelium was not as thick in the DES group as in the ST group, it was thicker than in the 
NiTi group, and the alteration of the epithelium was statistically greater due to its destruction 
(p<0.001). Overall, squamous metaplasia was not as significant in the DES groups in the ST 
group, although it was statistically higher in the central segment (40% of cases, p=0.020). 
Granulomas were detected in segment 0 in 10% of the cases and in segments 4 and D in the 
same proportion as NiTi group. Inflammation was primarily composed of lymphocytes and 
histiocytes, suggesting a chronic response. Neovascularization was also higher in the DES 
group compared to the NiTi group, but lower than in the ST group.  
Correlation between the CT and Histological Studies 
  
 
A positive correlation was calculated between epithelial thickening, as observed in the 
microscopic study, and stenosis degree, as detected by CT, at day 90 in 68.9% of cases. 
However, correlation of granuloma detection between the two techniques was not statistically 
significant (p=0.880). 
CONCLUSIONS 
The treatment of choice for symptomatic lesions of the airway is surgical resection, but 
sometimes other treatment alternatives are required, with or without placement of silicone 
stents. For tracheobronchial lesions in which surgery is not possible, stenting is an alternative. 
The use of self-expandable or balloon-expandable metallic stents has spread to treat 
obstructive or stenotic diseases throughout the body. With increasing frequency, many 
doctors are deploying expandable metallic stents for the management of patients with diverse 
endobronchial disorders 13. 
The self-expandable nitinol stent has shown the best results in both benign and malignant 
lesions of the tracheobronchial tree 14, 15. However, there has not been a comparative study or 
series of sufficient sample size to substantiate these results. Our study compared stents of two 
different types of metals (steel and nitinol alloy). Due to the favorable results of DES in 
avoiding restenosis in other areas of the body, a third stent made of nitinol, coated with 
paclitaxel, was also included. 
The rabbit trachea is known as very reactive, therefore, we chose this species to assess 
tracheal wall responses to metallic stents 16. Furthermore, percutaneous stenting in this animal 
model is an easy, quick and effective procedure. The five different segments that were 
analyzed in each sample were useful to evaluate the entire tracheal reactivity and stenosis 
location. 
  
 
Steel stents were first used in the tracheobronchial tree with initially favorable results, but 
quickly revealed shortcomings 3, 17, 18. In De Gregorio et al. study, three out of four steel stents 
that were used to treat benign lesions in the trachea had to be removed a year after their 
deployment 18. We have corroborated these findings in our study. In fact, mortality was 
highest in the steel stent group (80%) due to stenosis and infection. Foreign body response 
and mucus accumulation increased likelihood of infection. Pneumonia was found at necropsy 
and Pasteurella multocida was isolated as the causal agent because it proliferated due to the 
poor condition of the airway of the animals because of stent deployment. Tracheal stenosis 
and granulomas in our CT study were, as expected, more significant in the ST group 
compared to the NiTi group. 
Bare, nitinol self-expanding stents had the best performance in both benign and malignant 
stenotic lesions of the tracheobronchial tree. Several authors have reported acceptable results 
with this type of stent 8, 20-22. Our study shows a low rate of epithelial lesions and granulomas 
in tracheas treated with bare, nitinol stents, as well. 
The main cause of restenosis, post-stenting, is tracheal wall thickening due to granuloma 
formation 23, 24. Our initial hypothesis was that a paclitaxel DES would improve the results 
since epithelial reaction would be reduced. Nevertheless, 50% of DES cases developed 
granulomas in the central segment of the stent at day 30 (p=0.010) and in the segment 0 at day 
90 (p=0.018) in the CT study. Remarkable epithelial destruction was also observed in this 
group. These results are comparable to Arellano at al. in vitro study, where these DES 
provoke a prompt and remarkable cellular destruction in fibroblasts cultures.25  
Few studies of DES stents in the treatment of airway stenosis have been performed. One 
report presented a positive effect of a mitomycin C-eluting, bioabsorbable stent implanted in 
the trachea of rabbits, in comparison to four other types of stents 26. Several authors also have 
  
 
used paclitaxel-eluting stents in the treatment of patients with emphysema to maintain airway 
patency 27-30. Although the results were initially promising, the improvement was only 
temporary. Except for the airway bypass stents for emphysema, DES are not clinically 
indicated for airway stenting and futures studies may focus on this issue as a way to prevent 
granulomas, reduce stent colonization with bacteria and fungi, etc. 
Our comparative study agreed with published results for the steel and bare nitinol stents but 
the findings that we observed in the DES group were surprisingly negative. DES caused 
severe alterations in all the layers of the tracheal wall, even affecting the cartilage. In order to 
explain these findings, we hypothesize that the conditions of a DES differ according to 
location. The correct drug dosage is also important in order to avoid tissue damage 31. In 
another study, high paclitaxel concentration was associated with a worse response in the 
biliary duct 32. The biliary duct and tracheal wall both have different histological structures 
compared to vessels, where the use of DES has been most effective. Furthermore, blood flow 
produces a continuous lavage of drug in the vasculature that is not present in other locations, 
providing a possible explanation for the paclitaxel overdose in the airway in our study. 
Moreover, the radial forces exerted by the stents in the airway lumen against the airway wall 
is important in this model, but the design and size of DES and NiTi are the same so 
differences are due to the drug.  
The main limitation of this study is that it was conducted in laboratory animals. The tracheal 
anatomy and reactivity of the rabbit is similar, but not identical, to humans. In addition, due to 
the small size, we used stents commercialized for vascular use, with a fixed drug 
concentration. Data from day 90 in ST group is probably not representative because of the 
high mortality before this day (80%). 
  
 
In conclusion, our study confirms the previously reported effects of steel stents, which caused 
granulomas and significant stenosis. Nitinol stents were the least reactive of the assessed 
stents. DES caused significant lesions with destruction in all layers of the trachea, possibly 
related to drug dosage.  
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FIGURE LEGENDS 
Figure 1: Fluoroscopically-guided percutaneous stent implantation. 
 
Figure 2: (A) Axial, coronal and sagittal views of stenosis at the segments in contact with the 
stent in a rabbit from the DES group at day 30. (B) Axial, coronal, and sagittal views of a 
suspected granuloma, located in segment 0, in a rabbit from the ST group at day 30.  
  
 
 
 
Figure 3: Images of a suspected granuloma. (A) CT image,sagittal view with the appearance 
of granuloma. (B) Macroscopic view of granuloma. (C) Microscopic view (10X) of 
granuloma around the struts of the stent. (D) Microscopic view (60X) of a giant cell. 
  
 
 
Figure 4: Anatomopathological images of the tracheal responses to the assessed stents. First 
row, gross anatomy; second row, epithelium thickness; third row, epithelium alterations. 
Haematoxyline-eosin, 60x. 
  
 
 
TABLES 
Table 1. Scores in CT and AP Studies 
Study Parameter Score 
Total score is the sum of 
the values of the five 
sections(P,0,2,4,D) 
CT 
Stenosis 
percentage 
0: 0 % 
1: 1-20 % 
2: 21-40 % 
3: 41-60 % 
4: 61-80 % 
5: >80 % 
Minimum value = 0 
Maximum value =25 
AP 
Epithelium 
thickening 
0: Normal <50 µm 
1: Mild: 50-100 µm 
2: Moderate: 100-150 µm 
3: Severe: >150 µm 
Minimum value = 0 
Maximum value = 15 
AP 
Subepithelial 
thickening 
0: Normal ≤400 µm 
1: Mild: 400-600 µm, 
2: Moderate: 600-800 µm 
3: Severe: >800 µm 
Minimum value = 0 
Maximum value = 15 
  
 
AP 
Granuloma 
formation 
0: Absent 
1: One granuloma 
2: More than one granuloma 
Minimum value = 0 
Maximum value = 10 
CT: computerized tomography 
AP: Anatomopathological study 
P, 0, 2, 4 D: Tracheal sections assessed (P, tissue immediately cranial to the proximal end of the stent; 0, 
proximal end of the stent; 2, central part of the stent; 4, distal end of the stent; and D, tissue immediately caudal 
to the distal end of the stent) 
 
Table 2: Stenosis Assessment in the CT Study 
Maximum tracheal stenosis (%) and location at days 30 and 90 
Group 
Day 30 Day 90 
Mean  ±  SD Segment Mean  ±  SD Segment 
Control 0.00 ± 0.00 - 0.00 ± 0.00 - 
ST 15.54 ± 25.95  P 13.63 ± 19.28  0 
NiTi 2.86 ± 6.91  2 3.45 ± 5.14  2 
DES 11.28 ± 13.98 2 16.88 ± 13.82  2 
 Stenosis length (mm) in CT scans at days 30 and 90 
Group Day 30 Day 90 
 n Mean  ±  SD min Max n Mean  ±  SD min Max 
ST 6 6.57  ±  6.54a 0.0 16.5 2 14.55 ± 12.52a 5.7 23.4 
NiTi 8 5.84  ±  12.43a 0.0 36.0 8 8.19 ± 11.64a 0.0 34.7 
DES 8 20.51 ± 14.08b 0.0 39.2 6 21.62 ± 3.94a 16.0 28.2 
p-value *  0.043    0.065   
* ANOVA test. Values with the same superscript indicate no statistical differences between them 
according to Duncan´s test. 
ST, steel stent group; NiTi, nitinol stent group;,DES, nitinol drug eluting stent group. P,tissue immediately 
cranial to the proximal end of the stent; 0, proximal end of the stent; 2, central part of the stent. 
 
Table 3. Tracheal Lumen Stenosis (Scores, maximum = 25) 
 
 Day 30 Day 90  
 n Mean  ±  SD n Mean  ±  SD p-value* 
Control 10 0.00 ± 0.00a 9 0.00 ± 0.00a >0.999 
ST 6 3.00 ± 3.22c 2 2.50 ± 2.12b 0.180 
NiTi 8 0.63 ± 1.06ab 8 1.00 ± 1.07a 0.180 
  
 
DES 8 2.38 ± 1.92bc 6 2.83 ± 1.33b 0.357 
p-value ** 0.006 <0.001  
* Wilcoxon test significance 
** Kruskal-Wallis test significance 
Values with the same superscript indicate no statistical differences between them according to paired Mann-
Whitney U test 
Table 4. Assessment of Histological Parameters (Scores) 
Epithelium thickening (maximum = 15) n Mean  ±  SD min Max 
Control 10 0.00 ± 0.00a 0 0 
ST 10 5.50 ± 1.77b 3 8 
NiTi 10 2.13 ± 2.75c 0 8 
DES 10 3.67 ± 1.21c 2 5 
p-value*  <0.001     
Subepithelial thickening (maximum = 15) 
Control 10 0.10 ± 0.32a 0 1 
ST 10 7.56 ± 2.7b 4 11 
NiTi 10 2.38 ± 2.83ac 0 7 
DES 10 4.00 ± 3.74c 0 12 
p-value*  <0.001     
Granuloma formation (maximum = 10) 
Control 10 0.00 ± 0.00a 0 0 
ST 10 1.11 ± 0.78b 0 2 
NiTi 10 0.25 ± 0.70a 0 2 
DES 10 0.30 ± 0.67a 0 2 
p-value*  <0.001     
 
*Kruskal-Wallis test significance,  
Values with the same superscript indicate no statistical differences between them according to paired Mann-
Whitney U test 
 
 
